Brief: Intensity Therapeutics Says Pursuant To Collaboration Deal, Co To Supply SAKK With INT230-6 As Well As Funding In Amount Of Up To About $3 Mln
Brief: Intensity Therapeutics-Got Nasdaq Letter Due To Resignation Of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Brief: Immuno-Oncology Company Portage Biotech Completes Monetization of Intensity Therapeutics Shares
Brief: Intensity Therapeutics Provides Update on Progress In Phase 3 Sarcoma Program
Brief: Intensity Therapeutics Appoints Joseph Talamo, CPA, As CFO
U.S. STOCKS ON THE MOVE-Paramount Global, Enphase Energy, bluebird bio
U.S. STOCKS ON THE MOVE-VerifyMe, Coherus BioSciences, bluebird bio
Intensity Therapeutics rises on positive breast-cancer study data
Brief: Intensity Therapeutics Shares More Than Double To $8.79 Premarket After Co Reports Positive Mid-Stage Trial Data For Breast Cancer Drug
U.S. STOCKS ON THE MOVE-Kodiak Sciences, Intensity Therapeutics, Inovio Pharma
U.S. STOCKS ON THE MOVE-Kodiak Sciences, Intensity Therapeutics, Inovio Pharma
Intensity Therapeutics jumps on FDA's 'orphan drug' tag for cancer treatment
Brief: Intensity Therapeutics Receives Orphan Drug Designation For The Three Key Ingredients In Int230-6 For The Treatment Of Soft Tissue Sarcoma
Brief: Intensity Therapeutics, Inc. Announces The Closing And Full Exercise Of The Over-Allotment Option From Its Upsized Initial Public Offering, Raising A Total Of $22.425 Million In Gross Proceeds
Brief: Intensity Therapeutics Closes Of Upsized Initial Public Offering Raising About $19.5 Mln In Gross Proceeds
Brief: Intensity Therapeutics Announces Pricing Of Upsized Initial Public Offering, Raising Approximately $19.5 Mln In Gross Proceeds